share_log

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17

b. Riley Securities維持對Bicycle Therapeutics的中立評級,將目標價下調至17美元
Benzinga ·  12/14 01:38  · 評級/大行評級

B. Riley Securities analyst Kalpit Patel maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Neutral and lowers the price target from $28 to $17.

b. Riley Securities 分析師 Kalpit Patel 維持 Bicycle Therapeutics (納斯達克:BCYC) 的中立評級,並將目標價從28美元下調至17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論